Cellectis S.A.
Developing allogeneic CAR T-cell cancer immunotherapies using TALEN® gene-editing technology.
CLLS | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 8 RUE DE LA CROIX JARRY, 0 PARIS, LLE-DE-FRANCE
- Website:
- https://www.cellectis.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of cancer immunotherapies. The company leverages its proprietary gene-editing technology, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Cellectis focuses on creating allogeneic, or "off-the-shelf," CAR T-cell product candidates from healthy donor cells. This approach aims to provide broadly available and scalable treatments for a large number of patients, in contrast to personalized autologous therapies. The company's technology is designed to solve key challenges in allogeneic cell therapy, including Graft-versus-Host Disease (GvHD) and host-versus-graft rejection. Cellectis maintains a strong intellectual property portfolio and collaborates with global strategic partners to advance its therapeutic pipeline.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cellectis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
